Background The main therapeutic treatments for hepatic artery complications after orthotopic liver transplantation （OLT） include thrombolysis, percutaneous transluminal angioplasty, stent placement, and liver retran...Background The main therapeutic treatments for hepatic artery complications after orthotopic liver transplantation （OLT） include thrombolysis, percutaneous transluminal angioplasty, stent placement, and liver retransplantation. The prognosis of hepatic artery complications after OLT is not only related to the type, extent, and timing but also closely associated with the selection and timing of the therapeutic methods. However, there is no consensus of opinion regarding the treatment of these complications. The aim of this study was to determine optimal treatment for hepatic artery complications after OLT. Methods The clinical data of 25 patients diagnosed with hepatic artery thrombosis （HAT） and hepatic artery stenosis （HAS） between October 2003 and March 2007 were retrospectively reviewed. Treatments included liver retransplantation and interventions which contain thrombolysis, percutaneous transluminal angioplasty and stent placement. Results Among five patients with HAT, 3 were treated with thrombolysis. One recovered, one died after thrombolysis and another one died of multi-organ failure after retransplantation because of recurrent HAT. The remaining 2 patients underwent successful retransplantation and have survived after that. Among 12 patients presented with HAS within 1 month postoperatively, 2 patients underwent retransplantation due to irreversible liver failure and another 10 patients were treated with interventions. The liver function failed to improve in 3 patients and retransplantations were performed in 4 patients after stent placement because of ischemic cholangitis. Among 6 patients undergoing liver retransplantations, two died of intracranial hemorrhage and infection respectively. Eight patients presented with HAS after 1 month postoperatively, 5 patients were treated with interventional management and recovered after stent placement. Among another 3 patients presented with HAS, 2 patients’ liver function was stable and one patient received late liver retransplantation due to ischemic bile duct lesion. Conclusions Individualized therapeutic regimens should be adopted in treating hepatic artery complications after OLT, according to postoperative periods, types and whether ischemic bile duct lesion exists or not. Liver retransplantation is the best treatment for patients with hepatic artery thrombosis. Interventional treatments of late HAS without irreversible liver failure or bile duct ischemia are appropriate, whereas retransplantation is recommended for early HAS.展开更多
目的探讨支架置入治疗肝移植术后肝动脉狭窄(HAS)的可行性及临床效果。方法回顾性分析13例肝移植术后经肝动脉造影证实、并行肝动脉支架置入(12例)或经皮腔内血管成形术(PTA)治疗(1例)的 HAS 患者的临床资料及支架置入技术要点。结果 1...目的探讨支架置入治疗肝移植术后肝动脉狭窄(HAS)的可行性及临床效果。方法回顾性分析13例肝移植术后经肝动脉造影证实、并行肝动脉支架置入(12例)或经皮腔内血管成形术(PTA)治疗(1例)的 HAS 患者的临床资料及支架置入技术要点。结果 13例患者中,11例成功置入支架,1例 PTA 加支架置入失败,1例单纯 PTA 治疗成功。支架术后随访9～227 d,平均97 d,无一例术后发生支架内再狭窄。诊疗时距在2周内的7例患者,1例支架置入术后9 d 死于多器官功能衰竭,6例术后血清转氨酶和(或)胆红素恢复正常;而诊疗时距大于2周的4例患者,1例死于胆道感染引起的败血症和肝功能衰竭,3例血清胆红素仍高于正常、反复出现胆道感染,经抗感染和(或)胆道引流病情好转。结论支架治疗肝移植术后 HAS 是可行的,指引导管或长鞘技术和冠状动脉支架的应用可提高支架置入技术的成功率。早期诊断、早期治疗是影响支架置入疗效的关键因素。展开更多
基金This study was supported by grants from the Major State Basic Research Development Program （973 Program） of China （No. 2003CB515500）, the National Natural Science Foundation of China （No. 30571769 and No. 30772044）, Sci-tech Research Development Program of Guangdong Province （No. 2007A032000001 and No. 2007B060401033）, and the Teamwork Projects Funded by Guangdong Natural Science Foundation （No. 05200177）.
文摘Background The main therapeutic treatments for hepatic artery complications after orthotopic liver transplantation （OLT） include thrombolysis, percutaneous transluminal angioplasty, stent placement, and liver retransplantation. The prognosis of hepatic artery complications after OLT is not only related to the type, extent, and timing but also closely associated with the selection and timing of the therapeutic methods. However, there is no consensus of opinion regarding the treatment of these complications. The aim of this study was to determine optimal treatment for hepatic artery complications after OLT. Methods The clinical data of 25 patients diagnosed with hepatic artery thrombosis （HAT） and hepatic artery stenosis （HAS） between October 2003 and March 2007 were retrospectively reviewed. Treatments included liver retransplantation and interventions which contain thrombolysis, percutaneous transluminal angioplasty and stent placement. Results Among five patients with HAT, 3 were treated with thrombolysis. One recovered, one died after thrombolysis and another one died of multi-organ failure after retransplantation because of recurrent HAT. The remaining 2 patients underwent successful retransplantation and have survived after that. Among 12 patients presented with HAS within 1 month postoperatively, 2 patients underwent retransplantation due to irreversible liver failure and another 10 patients were treated with interventions. The liver function failed to improve in 3 patients and retransplantations were performed in 4 patients after stent placement because of ischemic cholangitis. Among 6 patients undergoing liver retransplantations, two died of intracranial hemorrhage and infection respectively. Eight patients presented with HAS after 1 month postoperatively, 5 patients were treated with interventional management and recovered after stent placement. Among another 3 patients presented with HAS, 2 patients’ liver function was stable and one patient received late liver retransplantation due to ischemic bile duct lesion. Conclusions Individualized therapeutic regimens should be adopted in treating hepatic artery complications after OLT, according to postoperative periods, types and whether ischemic bile duct lesion exists or not. Liver retransplantation is the best treatment for patients with hepatic artery thrombosis. Interventional treatments of late HAS without irreversible liver failure or bile duct ischemia are appropriate, whereas retransplantation is recommended for early HAS.
文摘目的探讨支架置入治疗肝移植术后肝动脉狭窄(HAS)的可行性及临床效果。方法回顾性分析13例肝移植术后经肝动脉造影证实、并行肝动脉支架置入(12例)或经皮腔内血管成形术(PTA)治疗(1例)的 HAS 患者的临床资料及支架置入技术要点。结果 13例患者中,11例成功置入支架,1例 PTA 加支架置入失败,1例单纯 PTA 治疗成功。支架术后随访9～227 d,平均97 d,无一例术后发生支架内再狭窄。诊疗时距在2周内的7例患者,1例支架置入术后9 d 死于多器官功能衰竭,6例术后血清转氨酶和(或)胆红素恢复正常;而诊疗时距大于2周的4例患者,1例死于胆道感染引起的败血症和肝功能衰竭,3例血清胆红素仍高于正常、反复出现胆道感染,经抗感染和(或)胆道引流病情好转。结论支架治疗肝移植术后 HAS 是可行的,指引导管或长鞘技术和冠状动脉支架的应用可提高支架置入技术的成功率。早期诊断、早期治疗是影响支架置入疗效的关键因素。
